Evommune, Inc. (EVMN)
9.45
-0.20
(-2.07%)
USD |
NYSE |
Sep 21, 16:00
9.45
0.00 (0.00%)
After-Hours: 20:00
Evommune Enterprise Value : 157.96M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 157.96M |
| September 17, 2026 | 147.80M |
| September 16, 2026 | 147.80M |
| September 15, 2026 | 170.29M |
| September 14, 2026 | 186.26M |
| September 11, 2026 | 190.25M |
| September 10, 2026 | 190.97M |
| September 09, 2026 | 201.13M |
| September 08, 2026 | 282.40M |
| September 04, 2026 | 253.01M |
| September 03, 2026 | 243.22M |
| September 02, 2026 | 260.63M |
| September 01, 2026 | 260.63M |
| August 31, 2026 | 267.16M |
| August 28, 2026 | 287.84M |
| August 27, 2026 | 296.91M |
| August 26, 2026 | 319.77M |
| August 25, 2026 | 308.16M |
| August 24, 2026 | 303.81M |
| August 21, 2026 | 316.51M |
| August 20, 2026 | 300.18M |
| August 19, 2026 | 352.43M |
| August 18, 2026 | 323.76M |
| August 17, 2026 | 324.85M |
| August 14, 2026 | 339.36M |
| Date | Value |
|---|---|
| August 13, 2026 | 318.32M |
| August 12, 2026 | 320.14M |
| August 11, 2026 | 323.40M |
| August 10, 2026 | 318.32M |
| August 07, 2026 | 318.68M |
| August 06, 2026 | 293.29M |
| August 05, 2026 | 280.22M |
| August 04, 2026 | 283.49M |
| August 03, 2026 | 228.34M |
| July 31, 2026 | 216.01M |
| July 30, 2026 | 219.63M |
| July 29, 2026 | 208.75M |
| July 28, 2026 | 216.01M |
| July 27, 2026 | 223.99M |
| July 24, 2026 | 220.00M |
| July 23, 2026 | 218.55M |
| July 22, 2026 | 221.45M |
| July 21, 2026 | 251.20M |
| July 20, 2026 | 226.17M |
| July 17, 2026 | 248.30M |
| July 16, 2026 | 232.70M |
| July 15, 2026 | 259.54M |
| July 14, 2026 | 242.85M |
| July 13, 2026 | 246.85M |
| July 10, 2026 | 287.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.25M |
| Total Expenses (Quarterly) | 32.25M |
| EPS Diluted (Quarterly) | -0.8924 |
| Earnings Yield | -29.93% |
| Normalized Earnings Yield | -29.93 |